Ketotifen in chronic idiopathic urticaria

This is an open prospective study to see the efficacy and safety of ketotifen in chronic idiopathic urticaria in twenty patients including 9[45%] males and 11[55%] females of 9 years to 49 years of age [Average 28.6 years]. Duration of disease varied from 2 months to 5 years. One mg of ketotifen twice daily was given for 4 weeks with 3 month follow up. Ketotifen was effective and safe and effectively reduced the need of concomitant therapy in the treatment of chronic idiopathic urticaria